Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00069641 · ClinicalTrials.gov registry record · Phase 2
Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT00069641 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 96 participants.
The verdict
NCT00069641, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the administration of iduronate-2-sulfatase enzyme in a weekly or every other week therapy frequency is safe and efficacious in patients with MPS II.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Iduronate-2-sulfatase enzyme replacement therapy
- BIOLOGICAL iduronate-2-sulfatase enzyme replacement therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2003-09-18 |
| Est. Completion | 2005-03-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00069641
The ClinicalTrials.gov registry entry for NCT00069641 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00069641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00069641 about?
NCT00069641 is a clinical study titled "Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)". The purpose of this study is to determine whether the administration of iduronate-2-sulfatase enzyme in a weekly or every other week therapy frequency is safe and efficacious in patients with MPS II.
What is the current status of trial NCT00069641?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2003-09-18. Estimated completion is 2005-03-16.
What interventions are being tested in trial NCT00069641?
The interventions under investigation include: Placebo (BIOLOGICAL), Iduronate-2-sulfatase enzyme replacement therapy (BIOLOGICAL), iduronate-2-sulfatase enzyme replacement therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00069641?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.